Liraglutide is glucagon-like peptide-1 receptor agonist for treating patients with type 2 diabetes mellitus. Our previous studies have demonstrated that liraglutide protects cardiac function through improving endothelial function in patients with acute myocardial infarction undergoing percutaneous coronary intervention. The present study will… (More)
Figure 2. Liraglutide preserves ΔΨm of cardiomyocytes against H/R. Representative images of JC-1 fluorescence (A) and quantitative analysis of fluorescence intensity in H9C2 cells (B), bar = 30 μm. All values are presented as the mean ± SD, n = 3; **P < 0.01 vs. control group, #P < 0.05 vs. H/R group. ΔΨm was assessed by fluorescence microscopy using JC-1 probe in H9C2 cells incubated in normal condition or in simulated H/R condition or simulated in H/R condition plus pretreatment with liraglutide. The results showed H/R obviously decreased red fluorescence intensity and increased green fluorescence intensity, and liraglutide reversed the effect. The results indicate liraglutide preserves ΔΨm of cardiomyocytes and protect mitochondrial function in cardiomyocytes against H/R. Data were normalized as the ratio of red fluorescence to green fluorescence. H/R: hypoxia/reoxygenation; Lir: liraglutide.